Visceral leishmaniasis (VL) is a life threatening infectious disease caused by Leishmania
donovani. It leads to the severe immune suppression in the host defense system. Higher …

Present treatment regimen on visceral leishmaniasis has multiple limitations including
severe side effects, toxicity, and resistance of Leishmania strains. Amphotericin B is a well …

Visceral leishmaniasis (VL) is an endemic fatal infectious disease in tropical and subtropical
nations. The limited treatment options, long treatment regimens, invasive mode of …

Abstract In Northeastern Brazil visceral leishmaniasis is endemic with lethal cases among
humans and dogs. Treatment is toxic and 5–10% of humans die despite treatment. The aim …

The treatment against leishmaniasis presents problems, mainly due to their toxicity of the
drugs, high cost and/or by the emergence of parasite resistant strains. In this context, new …

A novel series of ester and carbamate derivatives was synthesized and evaluated its
activities against Leishmania amazonensis. All compounds exhibited weaker leishmanicidal …

Leishmaniasis is a parasite-mediated tropical disease affecting millions of individuals
worldwide. The available antileishmanial chemotherapeutic modalities exhibit adverse …

Leishmaniasis is a group of protozoan parasitic diseases caused by various Leishmania
species. The clinical manifestations range from skin abrasions to lethal infection in the …

Background The therapy of visceral leishmaniasis (VL) is limited by resistance, toxicity and
decreased bioavailability of the existing drugs coupled with dramatic increase in HIV-co …

Leishmaniasis is caused by several protozoan species of Leishmania, and being
endemically present in 98 countries around the world, it is also a severe public-health …